• Rallybio postponed the November 6, 2026, closing of its merger with Avenzo Therapeutics because conditions for listing its shares remain unmet.
• The parties continue seeking listing approvals for the transaction under their May 31, 2026, merger agreement.
• Funds for the previously announced cash distribution were not deposited with Computershare on November 5, 2026, following the postponement.
• The cash distribution's previously announced payment date and ex-dividend date may consequently be delayed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rallybio Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-452115), on November 06, 2026, and is solely responsible for the information contained therein.